Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised …

KP Asante, S Abdulla, S Agnandji, J Lyimo… - The Lancet infectious …, 2011 - thelancet.com
Summary Background The RTS, S/AS01 E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …
被引用次数：175 相关文章

Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised …

KP Asante, S Abdulla, S Agnandji, J Lyimo… - The Lancet Infectious …, 2011 - Elsevier
BACKGROUND: The RTS, S/AS01E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …

Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised …

KP Asante, S Abdulla, S Agnandji, J Lyimo… - The Lancet Infectious …, 2011 - infona.pl
The RTS, S/AS01E candidate malaria vaccine is being developed for immunisation of
infants in Africa through the expanded programme on immunisation (EPI). 8 month follow-up …

Safety and efficacy of the RTS, S/AS01 (E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a …

A Asante-Poku, S Abdulla, S Agnandji… - The Lancet infectious …, 2011 - edoc.unibas.ch
BACKGROUND: The RTS, S/AS01 (E) candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …

[引用][C] Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a …

KP ASANTE, S ABDULLA, N SALIM… - Lancet. Infectious …, 2011 - pascal-francis.inist.fr
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation
vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial CNRS Inist Pascal-Francis …

Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised …

KP Asante, S Abdulla, S Agnandji… - The Lancet …, 2011 - researchonline.lshtm.ac.uk
BACKGROUND: The RTS, S/AS01 (E) candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …
[PDF] academia.edu

[PDF][PDF] Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a …

KP Asante, S Abdulla, S Agnandji, J Lyimo… - Lancet Infect …, 2011 - academia.edu
Summary Background The RTS, S/AS01E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …
[PDF] core.ac.uk

[PDF][PDF] Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a …

KP Asante, S Abdulla, S Agnandji, J Lyimo… - Lancet Infect Dis, 2011 - core.ac.uk
Summary Background The RTS, S/AS01E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …

Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised …

KP Asante, S Abdulla, S Agnandji, J Lyimo… - 2011 - cabidigitallibrary.org
Abstract Background: The RTS, S/AS01E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …

Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised …

KP Asante, S Abdulla, S Agnandji… - Lancet Infectious …, 2011 - researchers.cdu.edu.au
Background: RTS, S/AS01E is the lead candidate malaria vaccine. We recently showed
efficacy against clinical falciparum malaria in 5–17 month old children, during an average of …